<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">ploscomp</journal-id>
<journal-title-group>
<journal-title>PLOS Computational Biology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1553-734X</issn>
<issn pub-type="epub">1553-7358</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PCOMPBIOL-D-16-00549</article-id>
<article-id pub-id-type="doi">10.1371/journal.pcbi.1005371</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Enzymology</subject><subj-group><subject>Enzyme chemistry</subject><subj-group><subject>Enzyme regulation</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Toxicology</subject><subj-group><subject>Toxicity</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Toxicology</subject><subj-group><subject>Toxicity</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Optimization</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Metabolism</subject><subj-group><subject>Metabolic pathways</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Enzymology</subject><subj-group><subject>Enzymes</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Enzymes</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Enzymology</subject><subj-group><subject>Enzyme kinetics</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Enzymology</subject><subj-group><subject>Enzyme chemistry</subject><subj-group><subject>Enzyme metabolism</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene expression</subject><subj-group><subject>Gene regulation</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Optimality principles reveal a complex interplay of intermediate toxicity and kinetic efficiency in the regulation of prokaryotic metabolism</article-title>
<alt-title alt-title-type="running-head">Optimality principles in prokaryotic metabolism prevent accumulation of toxic intermediates</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Ewald</surname> <given-names>Jan</given-names></name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Bartl</surname> <given-names>Martin</given-names></name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1886-7625</contrib-id>
<name name-style="western">
<surname>Dandekar</surname> <given-names>Thomas</given-names></name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Kaleta</surname> <given-names>Christoph</given-names></name>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001">
<label>1</label>
<addr-line>Research Group Theoretical Systems Biology, Department of Bioinformatics, Friedrich-Schiller-Universität Jena, Jena, Germany</addr-line>
</aff>
<aff id="aff002">
<label>2</label>
<addr-line>Department of Bioinformatics, Biocenter, Julius-Maximilians-Universität Würzburg, Würzburg, Germany</addr-line>
</aff>
<aff id="aff003">
<label>3</label>
<addr-line>Research Group Medical Systems Biology, Christian-Albrechts-Universität zu Kiel, Kiel, Germany</addr-line>
</aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Mahadevan</surname> <given-names>Radhakrishnan</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1">
<addr-line>University of Toronto, CANADA</addr-line>
</aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con">
<p>
<list list-type="simple">
<list-item>
<p><bold>Conceptualization:</bold> JE CK.</p>
</list-item>
<list-item>
<p><bold>Formal analysis:</bold> JE CK.</p>
</list-item>
<list-item>
<p><bold>Methodology:</bold> JE MB CK.</p>
</list-item>
<list-item>
<p><bold>Supervision:</bold> CK TD.</p>
</list-item>
<list-item>
<p><bold>Validation:</bold> JE CK.</p>
</list-item>
<list-item>
<p><bold>Visualization:</bold> JE.</p>
</list-item>
<list-item>
<p><bold>Writing – original draft:</bold> JE CK.</p>
</list-item>
<list-item>
<p><bold>Writing – review &amp; editing:</bold> JE MB TD CK.</p>
</list-item>
</list>
</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">c.kaleta@iem.uni-kiel.de</email></corresp>
</author-notes>
<pub-date pub-type="collection">
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>17</day>
<month>2</month>
<year>2017</year>
</pub-date>
<volume>13</volume>
<issue>2</issue>
<elocation-id>e1005371</elocation-id>
<history>
<date date-type="received">
<day>5</day>
<month>4</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>1</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-year>2017</copyright-year>
<copyright-holder>Ewald et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pcbi.1005371"/>
<abstract>
<p>A precise and rapid adjustment of fluxes through metabolic pathways is crucial for organisms to prevail in changing environmental conditions. Based on this reasoning, many guiding principles that govern the evolution of metabolic networks and their regulation have been uncovered. To this end, methods from dynamic optimization are ideally suited since they allow to uncover optimality principles behind the regulation of metabolic networks. We used dynamic optimization to investigate the influence of toxic intermediates in connection with the efficiency of enzymes on the regulation of a linear metabolic pathway. Our results predict that transcriptional regulation favors the control of highly efficient enzymes with less toxic upstream intermediates to reduce accumulation of toxic downstream intermediates. We show that the derived optimality principles hold by the analysis of the interplay between intermediate toxicity and pathway regulation in the metabolic pathways of over 5000 sequenced prokaryotes. Moreover, using the lipopolysaccharide biosynthesis in <italic>Escherichia coli</italic> as an example, we show how knowledge about the relation of regulation, kinetic efficiency and intermediate toxicity can be used to identify drug targets, which control endogenous toxic metabolites and prevent microbial growth. Beyond prokaryotes, we discuss the potential of our findings for the development of antifungal drugs.</p>
</abstract>
<abstract abstract-type="summary">
<title>Author summary</title>
<p>Understanding the guiding principles behind the evolution of metabolic networks and their regulation is of fundamental importance in a broad range of disciplines reaching from the identification of novel targets to treat infections to the utilization of microbial organisms in biotechnological production processes. In our study, we used an approach that allowed us to identify optimal regulatory strategies for the control of metabolic pathways in a scenario in which the intermediates of a metabolic pathway differ in their toxicity for the host organism. The results of our approach, whose validity we demonstrate through the large-scale analysis of pathway regulation in several thousand prokaryotic metabolic networks, show that toxic intermediates are often associated to strongly regulated enzymes. Additionally, transcriptional regulation preferably targets highly efficient enzymes thereby minimizing the effort in terms of protein production that is required to adjust the flux through a metabolic pathway. Moreover, in an example case, we show how knowledge about key targets of regulation can be used to identify novel antimicrobials that inhibit cellular growth through self-poisoning of the pathogen.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001659</institution-id>
<institution>Deutsche Forschungsgemeinschaft</institution>
</institution-wrap>
</funding-source>
<award-id>KA 3541/3</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Bartl</surname> <given-names>Martin</given-names></name>
</principal-award-recipient>
</award-group>
<award-group id="award002">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001659</institution-id>
<institution>Deutsche Forschungsgemeinschaft</institution>
</institution-wrap>
</funding-source>
<award-id>KA 3541/3</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Ewald</surname> <given-names>Jan</given-names></name>
</principal-award-recipient>
</award-group>
<award-group id="award003">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001659</institution-id>
<institution>Deutsche Forschungsgemeinschaft</institution>
</institution-wrap>
</funding-source>
<award-id>CRC/TR 124 FungiNet (Project B2)</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Ewald</surname> <given-names>Jan</given-names></name>
</principal-award-recipient>
</award-group>
<award-group id="award004">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001659</institution-id>
<institution>Deutsche Forschungsgemeinschaft</institution>
</institution-wrap>
</funding-source>
<award-id>CRC/TR 124 FungiNet (Project B2)</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Kaleta</surname> <given-names>Christoph</given-names></name>
</principal-award-recipient>
</award-group>
<award-group id="award005">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001659</institution-id>
<institution>Deutsche Forschungsgemeinschaft</institution>
</institution-wrap>
</funding-source>
<award-id>Excellence Cluster “Inflammation at Interfaces”</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Kaleta</surname> <given-names>Christoph</given-names></name>
</principal-award-recipient>
</award-group>
<award-group id="award006">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001659</institution-id>
<institution>Deutsche Forschungsgemeinschaft</institution>
</institution-wrap>
</funding-source>
<award-id>CRC/TR 124 FungiNet (Project B2)</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1886-7625</contrib-id>
<name name-style="western">
<surname>Dandekar</surname> <given-names>Thomas</given-names></name>
</principal-award-recipient>
</award-group>
<award-group id="award007">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100004963</institution-id>
<institution>Seventh Framework Programme</institution>
</institution-wrap>
</funding-source>
<award-id>AspMetNet</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1886-7625</contrib-id>
<name name-style="western">
<surname>Dandekar</surname> <given-names>Thomas</given-names></name>
</principal-award-recipient>
</award-group>
<funding-statement>We acknowledge support by the Deutsche Forschungsgemeinschaft to MB (KA 3541/3), JE (KA 3541/3 and CRC/TR 124 FungiNet, sub-project B2), TD (AspMetNet: antibiotics design, CRC/TR 124 FungiNet: sub-project B2) and CK (Excellence Cluster “Inflammation at Interfaces”, EXC306). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="8"/>
<table-count count="1"/>
<page-count count="19"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>The consideration of organisms from the point of view of evolutionary adaptation is at the core of a large number of biological considerations [<xref ref-type="bibr" rid="pcbi.1005371.ref001">1</xref>–<xref ref-type="bibr" rid="pcbi.1005371.ref005">5</xref>]. The utilization of optimality principles that reflect forces of adaptation is a frequently used tool in Systems Biology to identify states in models of biological systems that are more likely and thereby drastically reduces the feasible solution space. Prominent examples of such methods are constraint-based modeling approaches which frequently use the notion of an optimal distribution of (metabolic) resources to maximize growth rate [<xref ref-type="bibr" rid="pcbi.1005371.ref006">6</xref>] to identify the biologically most plausible fluxes within a metabolic network.</p>
<p>While most optimization approaches employed in Systems Biology are considering optimality in a balanced (growth) state, the optimality in the dynamics of adaptation has recently received increasing attention [<xref ref-type="bibr" rid="pcbi.1005371.ref007">7</xref>–<xref ref-type="bibr" rid="pcbi.1005371.ref010">10</xref>]. While optimal growth in a particular condition is of high evolutionary advantage in constant environments, evolutionary theory posits that especially in changing environmental conditions those organisms that minimize the variance in fitness during environmental changes prevail [<xref ref-type="bibr" rid="pcbi.1005371.ref011">11</xref>, <xref ref-type="bibr" rid="pcbi.1005371.ref012">12</xref>]. Minimization of variance in fitness in turn can be achieved through regulatory programs that allow organisms to quickly respond to environmental challenges [<xref ref-type="bibr" rid="pcbi.1005371.ref010">10</xref>, <xref ref-type="bibr" rid="pcbi.1005371.ref013">13</xref>].</p>
<p>In previous works, we have identified a plethora of mechanisms and regulatory strategies by which organisms can reduce response times to adapt metabolic fluxes [<xref ref-type="bibr" rid="pcbi.1005371.ref010">10</xref>, <xref ref-type="bibr" rid="pcbi.1005371.ref014">14</xref>, <xref ref-type="bibr" rid="pcbi.1005371.ref015">15</xref>] or minimize the time required to produce protein complexes [<xref ref-type="bibr" rid="pcbi.1005371.ref016">16</xref>]. Concerning regulatory networks controlling metabolic pathways, we have previously established that with increasing protein costs, the complexity of such programs increases [<xref ref-type="bibr" rid="pcbi.1005371.ref010">10</xref>, <xref ref-type="bibr" rid="pcbi.1005371.ref014">14</xref>]. Thus, pathways that require only small protein investment are frequently only controlled at a few key positions while all enzymes of a pathways are only regulated in a coordinated fashion, if pathway costs are high. The former mode of transcriptional control is referred to as sparse transcriptional regulation while the latter is called pervasive transcriptional regulation. For pathways with very high protein costs this even leads to the optimality of precisely timed activation programs targeting individual enzymes in a pathway [<xref ref-type="bibr" rid="pcbi.1005371.ref014">14</xref>].</p>
<p>An important problem that we did not consider in our previous works are differences in the toxicity of intermediates of metabolic pathways. Especially, after a change in environmental conditions, the adjustment of fluxes in a pathway can lead to a temporary build-up of intermediates [<xref ref-type="bibr" rid="pcbi.1005371.ref017">17</xref>, <xref ref-type="bibr" rid="pcbi.1005371.ref018">18</xref>]. While we considered a generic upper bound on all metabolites previously, there are large differences in the side-effects that intermediates can exert. Especially for highly toxic intermediates, an accumulation needs to be avoided and a rapid conversion into downstream, probably less toxic intermediates, is required. For example the toxic intermediate homoserine, which is a precursor of the amino acids threonine, methionine and isoleucine, is tightly controlled by a complex interplay of transcriptional regulation and feedback inhibition mechanisms [<xref ref-type="bibr" rid="pcbi.1005371.ref018">18</xref>, <xref ref-type="bibr" rid="pcbi.1005371.ref019">19</xref>]. In the other direction, the identification of specific regulatory programs that are utilized to avoid the accumulation of toxic intermediates is a promising avenue to discover novel endogenous antibiotics that allow to more efficiently kill pathogens through self-poisoning.</p>
<p>In this work, we use dynamic optimization to study how the toxicity of intermediates influences regulatory programs that control metabolic pathways. For such pathways, our optimization approach predicts a more focused regulation of enzymes that occur upstream of toxic intermediates. Moreover, there is a strong tendency of transcriptional regulation to target enzymes that are efficient in terms of catalytic activity as well as substrate affinity and possess less toxic upstream intermediates. Especially a focus on transcriptional regulation of efficient enzymes is surprising since it is often assumed that rate-limiting steps, which are catalyzed by inefficient enzymes, are key points of pathway control [<xref ref-type="bibr" rid="pcbi.1005371.ref020">20</xref>, <xref ref-type="bibr" rid="pcbi.1005371.ref021">21</xref>]. We validate our prediction through a detailed examination of the interplay between enzyme efficiency as well as transcriptional control in <italic>Escherichia coli</italic> and a study of the relationship between regulatory effort as well as intermediate toxicity in the metabolic networks of more than 5000 prokaryotes. Moreover, we illustrate the usefulness of our approach through a detailed investigation of the influence of intermediate toxicity on the production of endogenous toxic metabolites in lipopolysaccharide metabolism.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="sec003">
<title>Modeling approach</title>
<p>To model the toxicity of intermediates, we extended the optimization problem formulated by Wessely et al. [<xref ref-type="bibr" rid="pcbi.1005371.ref010">10</xref>] with the explicit consideration of toxicity of individual intermediates through concentration thresholds for each metabolite <italic>β</italic><sub><italic>i</italic></sub> (<xref ref-type="fig" rid="pcbi.1005371.g001">Fig 1A</xref>). The underlying ordinary differential equation system (ODE) describes a linear pathway converting a substrate <italic>S</italic> via five enzymatic reactions into a product <italic>P</italic> (see <xref ref-type="supplementary-material" rid="pcbi.1005371.s001">S1 Text</xref>). The selection of a five step linear pathway was made since it provides a good trade off between long and short linear pathways and is also the mean length of the defined linear pathways based on the listed pathways in MetaCyc [<xref ref-type="bibr" rid="pcbi.1005371.ref024">24</xref>]. Nevertheless, we obtain comparable results also for shorter and longer pathway lengths (see <xref ref-type="supplementary-material" rid="pcbi.1005371.s002">S2 Text</xref>).</p>
<fig id="pcbi.1005371.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005371.g001</object-id>
<label>Fig 1</label>
<caption>
<title/>
<p>(A) Model of a linear pathway used for optimization. The substrate <bold>S</bold> is converted to a product <bold>P</bold> via five reactions catalyzed by enzymes with the concentration <italic>e</italic><sub><italic>j</italic></sub>(<italic>t</italic>) with kinetic parameters <italic>k</italic><sub><italic>cat</italic></sub> and <italic>K</italic><sub><italic>m</italic></sub> and four intermediates <italic>X</italic><sub><italic>i</italic></sub> with concentration thresholds <italic>β</italic> that indicate their toxicity. The product <bold>P</bold> is diluted by <italic>v</italic><sub><italic>g</italic></sub> (dilution rate). (B) Objective function of the optimization problem. The objective function minimizes the regulatory effort of <italic>e</italic>(<italic>t</italic>) (green areas) and the initial concentration of enzymes <italic>e</italic>(0).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005371.g001" xlink:type="simple"/>
</fig>
<p>While the substrate of the pathway is assumed to be constant in concentration, the product undergoes a drain e.g. by growth or other environmental changes <italic>v</italic><sub><italic>g</italic></sub>(<italic>t</italic>), which vary over time:
<disp-formula id="pcbi.1005371.e001"><alternatives><graphic id="pcbi.1005371.e001g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005371.e001" xlink:type="simple"/><mml:math display="block" id="M1"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>v</mml:mi> <mml:mi>g</mml:mi></mml:msub> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>t</mml:mi> <mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mtd> <mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo> <mml:mfenced close="" open="{" separators=""><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi>g</mml:mi> <mml:mn>1</mml:mn></mml:msub> <mml:mo>,</mml:mo></mml:mrow></mml:mtd> <mml:mtd columnalign="left"><mml:mrow><mml:mi>t</mml:mi> <mml:mo>&lt;</mml:mo> <mml:mn>10</mml:mn></mml:mrow></mml:mtd></mml:mtr> <mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi>g</mml:mi> <mml:mn>2</mml:mn></mml:msub> <mml:mo>,</mml:mo></mml:mrow></mml:mtd> <mml:mtd columnalign="left"><mml:mrow><mml:mn>10</mml:mn> <mml:mo>≤</mml:mo> <mml:mi>t</mml:mi> <mml:mo>&lt;</mml:mo> <mml:mn>20</mml:mn></mml:mrow></mml:mtd></mml:mtr> <mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi>g</mml:mi> <mml:mn>3</mml:mn></mml:msub> <mml:mo>,</mml:mo></mml:mrow></mml:mtd> <mml:mtd columnalign="left"><mml:mrow><mml:mn>20</mml:mn> <mml:mo>≤</mml:mo> <mml:mi>t</mml:mi> <mml:mo>≤</mml:mo> <mml:mn>30</mml:mn></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mfenced></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives> <label>(1)</label></disp-formula>
The dilution is balanced by the regulation of the concentration of enzymes that catalyze the conversion of metabolites modeled as irreversible Michaelis-Menten kinetics with the parameters <italic>k</italic><sub><italic>cat</italic></sub> and <italic>K</italic><sub><italic>m</italic></sub>. As discussed previously [<xref ref-type="bibr" rid="pcbi.1005371.ref010">10</xref>], considering an outflow of the product through growth is conceptually identical to a change of product demand, but can be formulated more conveniently in the optimization approach. Results were found to be robust against variations in the preset changes of dilution rate <italic>v</italic><sub><italic>g</italic></sub>(<italic>t</italic>) (see <xref ref-type="supplementary-material" rid="pcbi.1005371.s002">S2 Text</xref>). Therefore the same changes in dilution rate <italic>v</italic><sub><italic>g</italic></sub>(<italic>t</italic>) like in Wessely et al. [<xref ref-type="bibr" rid="pcbi.1005371.ref010">10</xref>] were used for all optimization runs.</p>
<p>The toxicity of intermediates is simulated as constraints on the concentration of the metabolites:
<disp-formula id="pcbi.1005371.e002"><alternatives><graphic id="pcbi.1005371.e002g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005371.e002" xlink:type="simple"/><mml:math display="block" id="M2"><mml:mrow><mml:mn>0</mml:mn> <mml:mo>≤</mml:mo> <mml:msub><mml:mi>x</mml:mi> <mml:mi>i</mml:mi></mml:msub> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>t</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:mo>≤</mml:mo> <mml:msub><mml:mi>β</mml:mi> <mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></alternatives> <label>(2)</label></disp-formula></p>
<p>A biological interpretation of the toxicity threshold used in the optimization is, for instance, the half inhibitory concentration (IC50) of a metabolite, that is, the concentration at which half of a bacterial population is inhibited in its growth.</p>
<p>In the objective function we minimize two factors: the regulatory effort and protein costs. The regulatory effort is modeled as the deviation from initial enzyme concentrations and protein costs by the initial concentration of enzymes. Both objectives are weighted with the factor <italic>σ</italic>. Hence, the following objective function:
<disp-formula id="pcbi.1005371.e003"><alternatives><graphic id="pcbi.1005371.e003g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005371.e003" xlink:type="simple"/><mml:math display="block" id="M3"><mml:mtable displaystyle="true"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>F</mml:mi> <mml:mo>(</mml:mo> <mml:mi>e</mml:mi> <mml:mo>)</mml:mo></mml:mrow></mml:mtd> <mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo> <mml:munder><mml:mo form="prefix" movablelimits="true">min</mml:mo> <mml:msub><mml:mi>e</mml:mi> <mml:mrow><mml:mn>1</mml:mn> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>t</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:mo>,</mml:mo> <mml:mo>.</mml:mo> <mml:mo>.</mml:mo> <mml:mo>.</mml:mo> <mml:mo>,</mml:mo> <mml:msub><mml:mi>e</mml:mi> <mml:mn>5</mml:mn></mml:msub> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>t</mml:mi> <mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msub></mml:munder> <mml:mspace width="1.em"/><mml:munderover><mml:mo>∑</mml:mo> <mml:mrow><mml:mi>j</mml:mi> <mml:mo>=</mml:mo> <mml:mn>1</mml:mn></mml:mrow> <mml:mn>5</mml:mn></mml:munderover> <mml:mfenced close=")" open="(" separators=""><mml:munderover><mml:mo>∫</mml:mo> <mml:mrow><mml:mn>0</mml:mn></mml:mrow> <mml:msub><mml:mi>T</mml:mi> <mml:mrow><mml:mi>m</mml:mi> <mml:mi>a</mml:mi> <mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:munderover> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>σ</mml:mi> <mml:mo>·</mml:mo> <mml:munder><mml:munder accentunder="true"><mml:mrow><mml:msub><mml:mi>e</mml:mi> <mml:mi>j</mml:mi></mml:msub> <mml:mrow><mml:mo>(</mml:mo> <mml:mn>0</mml:mn> <mml:mo>)</mml:mo></mml:mrow></mml:mrow> <mml:mo>︸</mml:mo></mml:munder> <mml:mtext>abundance</mml:mtext></mml:munder> <mml:mo>+</mml:mo> <mml:munder><mml:munder accentunder="true"><mml:msup><mml:mrow><mml:mo>(</mml:mo> <mml:msub><mml:mi>e</mml:mi> <mml:mi>j</mml:mi></mml:msub> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>t</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:mo>-</mml:mo> <mml:msub><mml:mi>e</mml:mi> <mml:mi>j</mml:mi></mml:msub> <mml:mrow><mml:mo>(</mml:mo> <mml:mn>0</mml:mn> <mml:mo>)</mml:mo></mml:mrow> <mml:mo>)</mml:mo></mml:mrow> <mml:mn>2</mml:mn></mml:msup> <mml:mo>︸</mml:mo></mml:munder> <mml:mtext>regulation</mml:mtext></mml:munder> <mml:mo>)</mml:mo></mml:mrow> <mml:mi>d</mml:mi> <mml:mi>t</mml:mi></mml:mfenced></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></alternatives> <label>(3)</label></disp-formula>
is used to determine the optimal regulatory program. The factor <italic>σ</italic> models the costs for the whole pathway and not of single enzymes. In previous studies [<xref ref-type="bibr" rid="pcbi.1005371.ref014">14</xref>, <xref ref-type="bibr" rid="pcbi.1005371.ref016">16</xref>] we discovered that varying synthesis costs within the pathway can influence the regulatory strategy, but is neglected here to focus on the impact of toxic intermediates.</p>
<p>The model consists of several parameters with arbitrary units (<xref ref-type="table" rid="pcbi.1005371.t001">Table 1</xref>). The time-dependent concentrations of the five enzymes are used as control variables during the optimization. The simulation time span is set to 30 arbitrary time units and has no influence on optimization results (see also [<xref ref-type="bibr" rid="pcbi.1005371.ref015">15</xref>]). Parameters connected to toxicity (<italic>β</italic>) and kinetics (<italic>k</italic><sub><italic>cat</italic></sub>,<italic>K</italic><sub><italic>m</italic></sub>) are tested for their influence on optimal regulatory programs for two values of <italic>σ</italic> corresponding to high and low enzyme costs, respectively. To test the influence of toxicity and kinetic parameters, we performed 1000 runs in which their values were chosen randomly from the intervals indicated in <xref ref-type="table" rid="pcbi.1005371.t001">Table 1</xref>.</p>
<table-wrap id="pcbi.1005371.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005371.t001</object-id>
<label>Table 1</label>
<caption>
<title>Parameter and variable overview.</title>
</caption>
<alternatives>
<graphic id="pcbi.1005371.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005371.t001" xlink:type="simple"/>
<table border="0" frame="box" rules="all">
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Factor</th>
<th align="left">Value</th>
<th align="left">Description</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><italic>e</italic><sub><italic>j</italic></sub></td>
<td align="left">[0,∞]</td>
<td align="left">enzyme concentration (control variable)</td>
</tr>
<tr>
<td align="left"><italic>σ</italic></td>
<td align="left"><inline-formula id="pcbi.1005371.e004"><alternatives><graphic id="pcbi.1005371.e004g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005371.e004" xlink:type="simple"/><mml:math display="inline" id="M4"><mml:mfrac><mml:mn>1</mml:mn> <mml:mn>3</mml:mn></mml:mfrac></mml:math></alternatives></inline-formula> or <inline-formula id="pcbi.1005371.e005"><alternatives><graphic id="pcbi.1005371.e005g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005371.e005" xlink:type="simple"/><mml:math display="inline" id="M5"><mml:mfrac><mml:mn>1</mml:mn> <mml:mn>30</mml:mn></mml:mfrac></mml:math></alternatives></inline-formula></td>
<td align="left">weight of enzyme cost</td>
</tr>
<tr>
<td align="left"><italic>T</italic><sub><italic>max</italic></sub></td>
<td align="left">30</td>
<td align="left">timespan of optimization</td>
</tr>
<tr>
<td align="left"><italic>k</italic><sub><italic>cat</italic>,<italic>j</italic></sub></td>
<td align="left">[0,2]*</td>
<td align="left">turnover number</td>
</tr>
<tr>
<td align="left"><italic>K</italic><sub><italic>m</italic>,<italic>j</italic></sub></td>
<td align="left">[0,2]*</td>
<td align="left">inverse substrate affinity</td>
</tr>
<tr>
<td align="left"><italic>β</italic><sub><italic>i</italic></sub></td>
<td align="left">[0,4]*</td>
<td align="left">threshold of intermediate concentrations</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001">
<p>A star * indicates that the parameters are sampled from the indicated range.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec004">
<title>Dynamic optimization and analysis of simulation results</title>
<p>The above described optimization problem has time dependent and continuous decision (<italic>e</italic>(<italic>t</italic>)) and state variables (metabolite concentrations), and hence has to be solved using dynamic optimization. Similar to previous works [<xref ref-type="bibr" rid="pcbi.1005371.ref010">10</xref>, <xref ref-type="bibr" rid="pcbi.1005371.ref014">14</xref>, <xref ref-type="bibr" rid="pcbi.1005371.ref016">16</xref>], we used a quasi-sequential approach with the extensions of [<xref ref-type="bibr" rid="pcbi.1005371.ref022">22</xref>] to handle approximation errors and moving finite elements. Since this method is gradient-based, the optimization was repeated one hundred times for each random parameter set using random initializations to avoid local optima. For each random parameter set, we only considered the solution with the best objective function value.</p>
<p>To investigate the influence of kinetic and toxicity parameters on optimal regulatory programs, 1000 randomly distributed parameter samples were obtained as Sobol-sequences [<xref ref-type="bibr" rid="pcbi.1005371.ref023">23</xref>], which are values quasi-randomly distributed in the parameter space. In contrast to randomly chosen parameters sets, values obtained from a Sobol-sequence are maximizing the distance to each other in the parameter space. This leads to an optimal coverage of the parameter space and therefore less parameter tests are needed.</p>
<p>We are specifically interested in the relationship between regulatory effort, measured as deviation of enzyme time-courses from initial enzyme concentrations, and toxicity as well as kinetic parameters. To investigate this relationship, we partitioned the randomized parameters sets depending on the amount of regulatory effort at the individual pathway positions. Subsequently, we compared the distribution of toxicity parameters <italic>β</italic> and enzyme efficiency <inline-formula id="pcbi.1005371.e006"><alternatives><graphic id="pcbi.1005371.e006g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005371.e006" xlink:type="simple"/><mml:math display="inline" id="M6"><mml:mrow><mml:msub><mml:mi>k</mml:mi> <mml:mtext mathvariant="italic">eff</mml:mtext></mml:msub> <mml:mo>=</mml:mo> <mml:mstyle displaystyle="false" scriptlevel="0"><mml:mfrac><mml:msub><mml:mi>k</mml:mi> <mml:mrow><mml:mi>c</mml:mi> <mml:mi>a</mml:mi> <mml:mi>t</mml:mi></mml:mrow></mml:msub> <mml:msub><mml:mi>K</mml:mi> <mml:mi>m</mml:mi></mml:msub></mml:mfrac></mml:mstyle></mml:mrow></mml:math></alternatives></inline-formula> for cases with the 10% highest and lowest regulatory effort at individual pathway positions. To make regulatory effort comparable across the parameter samples, for each enzyme the fraction of regulation is normalized by dividing the regulatory effort with the sum of regulatory effort of all enzymes. Thus, the total normalized regulatory effort sums to one.</p>
</sec>
<sec id="sec005">
<title>Validation of optimization results in prokaryotes</title>
<p>As depicted in <xref ref-type="fig" rid="pcbi.1005371.g002">Fig 2</xref>, we validated regulatory programs predicted by the optimization approach using genomic data of pathways and the corresponding enzymes as well as compound toxicity from more than 5000 prokaryotic organisms represented in the BioCyc database (version 19.0) [<xref ref-type="bibr" rid="pcbi.1005371.ref024">24</xref>].</p>
<fig id="pcbi.1005371.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005371.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Overview of data and its processing for validation of optimization results.</title>
<p>Rectangles depict the used databases and colors indicate, similar to the other figures, the considered pathway characteristics. A scheme of a 8-step linear pathway visualizes the binning into 5 intervals for the validation process.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005371.g002" xlink:type="simple"/>
</fig>
<p>Pathway structures containing reactions and compounds were extracted from the MetaCyc database [<xref ref-type="bibr" rid="pcbi.1005371.ref024">24</xref>] and linear pathways were obtained as described previously [<xref ref-type="bibr" rid="pcbi.1005371.ref010">10</xref>, <xref ref-type="bibr" rid="pcbi.1005371.ref015">15</xref>]. Since kinetic parameters are only available on a large-scale for a few model organisms, we validated the corresponding hypotheses only for <italic>Escherichia coli</italic> based on experimentally measured kinetic parameters from the Brenda database [<xref ref-type="bibr" rid="pcbi.1005371.ref025">25</xref>]. Only kinetic parameters without the term ‘mutant’ in the description of the experimental setup were considered.</p>
<p>As an estimate of regulatory effort targeted at individual enzymes, we used the promoter length and the number of predicted post-translational modification (PTM) sites as reference. We used predicted PTM-sites as estimator for post-translational regulation since they offer a view on non-transcriptional regulation. Predicted as well as experimentally validated PTM-Sites were obtained from dbPTM [<xref ref-type="bibr" rid="pcbi.1005371.ref026">26</xref>]. In a previous work we showed that promoter length, defined as intergenic distance between adjacent genes, is a good estimator of the number of transcription factors targeting a gene and hence of the complexity of the transcriptional regulatory network controlling this gene [<xref ref-type="bibr" rid="pcbi.1005371.ref015">15</xref>]. We showed this through a strong correlation between the number of transcription factors targeting a gene with its promoter length and a significant correlation between codon adaptation indices, a genomic measure of protein abundance [<xref ref-type="bibr" rid="pcbi.1005371.ref027">27</xref>], as well as promoter length (more abundant proteins tend to be controlled by more complex regulatory networks).</p>
<p>Since experimentally determined toxicity of compounds is only available for a small number of metabolites and organisms, the prediction tool EcoliTox was used [<xref ref-type="bibr" rid="pcbi.1005371.ref028">28</xref>]. This tool is based on a quantitative structure activity relationship (QSAR) model built on measured IC50 values, which is the concentration of a compound where 50% of the bacterial growth is inhibited. The QSAR-model was obtained through training of an classifier on a library of 166 molecules whose toxicity was experimentally determined in <italic>E. coli</italic>. Predicted logarithmized <italic>IC</italic><sub>50</sub> values for all compounds listed in the MetaCyc database were kindly provided by Dr. Pablo Carbonell.</p>
<p>We focused our analysis on sparsely regulated metabolic pathways, since, in contrast to pervasively regulated metabolic pathways, only the most important enzymes are under transcriptional control in such pathways and influence of intermediate toxicity is stronger. In accordance to our previous work [<xref ref-type="bibr" rid="pcbi.1005371.ref015">15</xref>], sparsely regulated pathways were defined at those with an average promoter length below 60% of the promoter length of non-metabolic genes of the same organism. Enzyme positions were normalized to a range of [0,1] by
<disp-formula id="pcbi.1005371.e007"><alternatives><graphic id="pcbi.1005371.e007g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005371.e007" xlink:type="simple"/><mml:math display="block" id="M7"><mml:mrow><mml:mi>r</mml:mi> <mml:mi>e</mml:mi> <mml:mi>l</mml:mi> <mml:mi>a</mml:mi> <mml:mi>t</mml:mi> <mml:mi>i</mml:mi> <mml:mi>v</mml:mi> <mml:mi>e</mml:mi> <mml:mspace width="0.166667em"/><mml:mi>p</mml:mi> <mml:mi>o</mml:mi> <mml:mi>s</mml:mi> <mml:mi>i</mml:mi> <mml:mi>t</mml:mi> <mml:mi>i</mml:mi> <mml:mi>o</mml:mi> <mml:mi>n</mml:mi> <mml:mo>=</mml:mo> <mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>p</mml:mi> <mml:mi>o</mml:mi> <mml:mi>s</mml:mi> <mml:mi>i</mml:mi> <mml:mi>t</mml:mi> <mml:mi>i</mml:mi> <mml:mi>o</mml:mi> <mml:mi>n</mml:mi> <mml:mo>-</mml:mo> <mml:mn>1</mml:mn></mml:mrow> <mml:mrow><mml:mi>p</mml:mi> <mml:mi>a</mml:mi> <mml:mi>t</mml:mi> <mml:mi>h</mml:mi> <mml:mi>w</mml:mi> <mml:mi>a</mml:mi> <mml:mi>y</mml:mi> <mml:mspace width="0.166667em"/><mml:mi>l</mml:mi> <mml:mi>e</mml:mi> <mml:mi>n</mml:mi> <mml:mi>g</mml:mi> <mml:mi>t</mml:mi> <mml:mi>h</mml:mi> <mml:mo>-</mml:mo> <mml:mn>1</mml:mn></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:math></alternatives> <label>(4)</label></disp-formula>
to make pathways comparable for different lengths. In order to apply the same approach of analysis as for the optimization results, enzymes were categorized into five intervals of their relative position, representing the five enzymes in the model (see <xref ref-type="fig" rid="pcbi.1005371.g002">Fig 2</xref>) and the average length of the used linear pathways (5.079). The intervals [0, 0.1] and [0.9, 1] contain mainly the first and the last enzyme and the three intervals in between were divided equally and correspond to the three intermediate enzymes. The binning of pathways into intervals was also made for different pathway lengths (three and seven steps), but was found either to short to resolve the linear pathway characteristics (for short pathways) or not to differ in results if more intervals were used (see <xref ref-type="supplementary-material" rid="pcbi.1005371.s002">S2 Text</xref>).</p>
<p>Promoter lengths, number of PTM-sites and <italic>log</italic> IC50-values were Z-transformed to make data comparable across different pathways and organisms:
<disp-formula id="pcbi.1005371.e008"><alternatives><graphic id="pcbi.1005371.e008g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005371.e008" xlink:type="simple"/><mml:math display="block" id="M8"><mml:mrow><mml:mi>Z</mml:mi> <mml:mrow><mml:mo>(</mml:mo> <mml:mi>x</mml:mi> <mml:mo>)</mml:mo></mml:mrow> <mml:mo>=</mml:mo> <mml:mstyle displaystyle="true" scriptlevel="0"><mml:mfrac><mml:mrow><mml:mi>x</mml:mi> <mml:mo>-</mml:mo> <mml:mi>a</mml:mi> <mml:mi>v</mml:mi> <mml:mi>g</mml:mi></mml:mrow> <mml:mrow><mml:mi>s</mml:mi> <mml:mi>d</mml:mi></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:math></alternatives> <label>(5)</label></disp-formula>
where <italic>Z</italic>(<italic>x</italic>) is the transformed, <italic>avg</italic> the mean and <italic>sd</italic> the standard deviation of the corresponding values <italic>x</italic> across the entire pathway.</p>
<p>To match the analysis of the optimization results, we defined strongly or weakly regulated intervals of linear pathways as those where the mean regulatory effort of the interval was among the 10% highest (strong regulation) or lowest (weak regulation) across all pathways. Results show similar tendencies and significance for higher thresholds (25%).</p>
<p>Subsequently, the underlying pathway characteristics, like intermediate toxicity, of strongly and weakly regulated pathways were compared for each interval (see <xref ref-type="supplementary-material" rid="pcbi.1005371.s004">S2 Fig</xref>) or intervals are condensed regarding the position of strongly or weakly regulated enzymes to directly validate the hypotheses. For the latter, intervals are combined before and after the strongly regulated enzyme, if positions of strongly regulated enzymes are not the reference regulatory strategy involving the first and the last enzyme.</p>
</sec>
</sec>
<sec id="sec006" sec-type="results">
<title>Results</title>
<sec id="sec007">
<title>Optimization of a linear metabolic pathway model considering toxic intermediates</title>
<p>In a first step, we analyzed the influence of the inclusion of toxicity constraints on general properties of pathway regulation. To this end, we determined the relative distribution of regulatory effort for each pathway position across the 1000 randomly sampled parameter combinations for the model including toxicity constraints. In accordance to our previous results [<xref ref-type="bibr" rid="pcbi.1005371.ref010">10</xref>], the regulatory effort was mainly targeted at the initial and the terminal enzyme for low protein costs (<inline-formula id="pcbi.1005371.e009"><alternatives><graphic id="pcbi.1005371.e009g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005371.e009" xlink:type="simple"/><mml:math display="inline" id="M9"><mml:mrow><mml:mi>σ</mml:mi> <mml:mo>=</mml:mo> <mml:mstyle displaystyle="false" scriptlevel="0"><mml:mfrac><mml:mn>1</mml:mn> <mml:mn>30</mml:mn></mml:mfrac></mml:mstyle></mml:mrow></mml:math></alternatives></inline-formula>, <xref ref-type="fig" rid="pcbi.1005371.g003">Fig 3A</xref>), corresponding to a sparse transcriptional regulation. For high enzyme costs (<inline-formula id="pcbi.1005371.e010"><alternatives><graphic id="pcbi.1005371.e010g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1005371.e010" xlink:type="simple"/><mml:math display="inline" id="M10"><mml:mrow><mml:mi>σ</mml:mi> <mml:mo>=</mml:mo> <mml:mstyle displaystyle="false" scriptlevel="0"><mml:mfrac><mml:mn>1</mml:mn> <mml:mn>3</mml:mn></mml:mfrac></mml:mstyle></mml:mrow></mml:math></alternatives></inline-formula>, <xref ref-type="fig" rid="pcbi.1005371.g003">Fig 3C</xref>) we observe a rather uniform distribution of regulatory effort across the entire pathway, corresponding to a pervasive transcriptional regulation. Interestingly, the variation is stronger under the scenario of low enzyme costs (± 26.0%) suggesting that the influence of parameters on the regulatory strategy is greater compared to high enzyme costs (± 8.9%) and the position of strongly regulated enzymes changes depending on the pathway characteristics.</p>
<fig id="pcbi.1005371.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005371.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Relationship between regulatory effort and intermediate toxicity for low (A,B) and high enzyme costs (C,D).</title>
<p>(A,C) The fraction of regulation is displayed in blue for each enzyme. (B,D) The intermediate toxicity is depicted in yellow (white) for the case of a strongly (weakly) regulated enzyme and the toxicity threshold of intermediates before and after (lower values indicate higher toxicity). All plots show the distribution of values as a combination of violin- and box-plots indicating median and 25–75% percentile.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005371.g003" xlink:type="simple"/>
</fig>
<p>To better understand the influence of parameters on the targets of regulation, we separated all parameter samples into cases with weak and strong regulation for the individual pathway positions (upper and lower 10% percentile) and compared the distribution of the corresponding parameter samples between those cases (see <xref ref-type="sec" rid="sec002">Material and Methods</xref>). Based on this separation, we compared toxicity (<xref ref-type="fig" rid="pcbi.1005371.g003">Fig 3B and 3D</xref>) and kinetic parameters across all enzymes for cases with strong or weak regulation at individual pathway positions (see <xref ref-type="supplementary-material" rid="pcbi.1005371.s003">S1 Fig</xref> for detailed plot).</p>
<p>For kinetic efficiency a clear tendency is visible that strongly regulated enzymes tend to be also highly efficient confirmed by a significant correlation (Spearman correlation <italic>r</italic> = 0.57, <italic>P</italic> &lt; 1 ⋅ 10<sup>−308</sup>) of <italic>k</italic><sub><italic>eff</italic></sub> and fraction of regulatory effort. The correlation calculation includes all optimization results and shows that our observations are valid not only for the extreme cases (strong or weak), which are chosen to depict our results. Moreover, we observe a strong influence of intermediate toxicity on pathway regulation. The relation of toxicity thresholds, where low values correspond to high toxicity, and regulatory effort reveals that strongly regulated enzymes are followed by intermediates with low toxicity thresholds (Spearman correlation <italic>r</italic> = −0.21, <italic>P</italic> &lt; 3 ⋅ 10<sup>−13</sup> and <xref ref-type="fig" rid="pcbi.1005371.g003">Fig 3B and 3D</xref>). We see that the highly regulated enzyme can be further upstream of the toxic intermediate (see <xref ref-type="fig" rid="pcbi.1005371.g004">Fig 4C</xref>). In contrast to this, direct upstream intermediates have preferably high toxicity thresholds meaning a lower toxicity (Spearman correlation <italic>r</italic> = 0.49, <italic>P</italic> &lt; 6 ⋅ 10<sup>−74</sup> and <xref ref-type="fig" rid="pcbi.1005371.g003">Fig 3B and 3D</xref>). This observation can be explained by a regulatory program that shifts regulation to enzymes with less toxic upstream intermediates that can accumulate during regulation as we see in the time course of metabolite concentrations (compare <xref ref-type="fig" rid="pcbi.1005371.g004">Fig 4A and 4B</xref>).</p>
<fig id="pcbi.1005371.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005371.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Comparison of optimal regulatory programs.</title>
<p>(A) Optimal time-course of enzyme (in red) and intermediate (in blue) concentrations for <italic>σ</italic> = 1/30, uniform kinetics and no toxicity. (B) Optimal solution for the same parameters apart the low toxicity threshold <italic>β</italic><sub>4</sub> = 0.1 of intermediate <italic>X</italic><sub>4</sub>. (C) Again the same parameters as in (A) apart the highly efficient third enzyme <italic>k</italic><sub><italic>eff,3</italic></sub> = 10. Threshold are depicted as black lines and the arbitrary time horizon ranging from 0 to 30 is discarded for lucidity.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005371.g004" xlink:type="simple"/>
</fig>
<p>Both observations are less pronounced in the scenario with high enzyme costs since the ensuing pervasive regulation leads to a coordinated regulation of all enzymes and thus a reduced accumulation of intermediates. This is most obvious by smaller median differences of the medians of parameter distributions between strongly and weakly regulated pathway models compared to the scenario of low enzyme costs (<xref ref-type="fig" rid="pcbi.1005371.g003">Fig 3B and 3D</xref> and <xref ref-type="supplementary-material" rid="pcbi.1005371.s003">S1 Fig</xref>).</p>
<p>To illustrate the influence of toxicity constraints on pathway regulation, we compared the optimal sparse regulation of a pathway without toxicity constraints and uniform enzyme efficiency (<xref ref-type="fig" rid="pcbi.1005371.g004">Fig 4A</xref>) to cases with a tight constraint on the concentration of the last intermediate (<xref ref-type="fig" rid="pcbi.1005371.g004">Fig 4B</xref>) and a highly efficient third enzyme (<xref ref-type="fig" rid="pcbi.1005371.g004">Fig 4C</xref>).</p>
<p>The dynamics for the reference parameter set involves regulation at the first and last position to optimally balance product drain. This leads to an accumulation of the last intermediate <italic>X</italic><sub>4</sub>, which is used as a buffer for the product (<xref ref-type="fig" rid="pcbi.1005371.g004">Fig 4A</xref>). The dynamics change completely if this intermediate is toxic (<xref ref-type="fig" rid="pcbi.1005371.g004">Fig 4B</xref>). In this case, the optimal regulatory target is the fourth enzyme and intermediate <italic>X</italic><sub>3</sub> accumulates, since the accumulation of intermediate <italic>X</italic><sub>4</sub> is avoided due its toxicity. Analogously, if the third enzyme is much more efficient, we see a shift in the regulatory effort toward this enzyme independently of the toxicity of intermediates (<xref ref-type="fig" rid="pcbi.1005371.g004">Fig 4C</xref>).</p>
<p>In order to verify the generality of our results, we applied the same analysis to models of shorter and longer linear pathways, pathways with product inhibition, reversible reactions and changes in rates of dilution of the product of the pathway. We could confirm our observations also after these modifications to our basic model (see <xref ref-type="supplementary-material" rid="pcbi.1005371.s002">S2 Text</xref>).</p>
</sec>
<sec id="sec008">
<title>Intermediate toxicity shapes the regulation of prokaryotic metabolic pathways</title>
<p>We validated the predictions of the optimization in an analysis of regulation in the metabolic networks of more than 5000 prokaryotes listed in the BioCyc database. Apart from the collection of metabolic pathways, this database contains predictions on the operonic structure of the listed organisms which allows us to reliably infer promoter lengths and hence regulatory effort targeted at individual genes in each organism. In the metabolic networks, linear pathways were identified and combined with data of predicted regulatory effort (promoter length, PTM-sites), intermediate toxicity and kinetic parameters (for <italic>Escherichia coli</italic>). Further, to make pathways comparable and to match our model, we defined five pathway intervals to which enzymes at different pathway positions were assigned (see <xref ref-type="sec" rid="sec002">Methods</xref>).</p>
<p>In a first step, we investigated the distribution of intermediate toxicity across the pathway positions collected in the MetaCyc database (see <xref ref-type="fig" rid="pcbi.1005371.g005">Fig 5</xref>). We observed that substrates and products of pathways have slightly higher IC50 values than intermediates of pathways (first and last interval compared to intervals in between, Mann–Whitney–Wilcoxon test, <italic>P</italic> = 0.019), that is they are less toxic. From an evolutionary point of view, this observation makes intuitively sense since substrates and products of pathways are usually present in higher concentration than intermediates that are only transiently formed [<xref ref-type="bibr" rid="pcbi.1005371.ref029">29</xref>]. This suggests that the structure of metabolism has been shaped by avoiding toxic intermediates as substrates or products of pathways. On the other hand, substrates and products of pathways might also be less toxic because cells had to adapt to their higher concentration in contrast to intermediates that are present in smaller quantities. Other optimization approaches suggested that the limited solvent capacity leads to low concentrations of intermediates to avoid high osmotic pressure in the cell [<xref ref-type="bibr" rid="pcbi.1005371.ref030">30</xref>].</p>
<fig id="pcbi.1005371.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005371.g005</object-id>
<label>Fig 5</label>
<caption>
<title/>
<p>Distribution of intermediate toxicity for each pathway interval of all compounds listed in metacyc (lower values indicate higher toxicity).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005371.g005" xlink:type="simple"/>
</fig>
<p>Similar to the analysis of the optimization results, we separated data sets into cases of strong and weak regulation at individual pathway positions. To this end, we defined for each pathway interval the 10% of enzymes with highest regulatory effort as strongly regulated and the 10% of enzymes with smallest regulatory effort as weakly regulated (see <xref ref-type="sec" rid="sec002">Methods</xref>). Since the optimality principle of avoiding toxic intermediates was more pronounced in the case of low enzyme costs in the simulations, we focused the validation on sparsely regulated metabolic pathways. The strongly regulated enzymes represent targets of regulation and the toxicity is compared of upstream intermediates, direct and further downstream intermediates with weakly regulated pathways at this position. The resulting data set compromises 1,012,285 reactions with enzymes as data points from 214,550 defined linear metabolic pathways across 5292 organisms (see <xref ref-type="supplementary-material" rid="pcbi.1005371.s005">S1 Table</xref>).</p>
<p>In accordance with the optimization results, we observed a significantly lower toxicity of intermediates before the strongly regulated enzymes (Mann–Whitney–Wilcoxon test, <italic>P</italic> &lt; 1 ⋅ 10<sup>−16</sup>, see <xref ref-type="fig" rid="pcbi.1005371.g006">Fig 6</xref>). A closer inspection of the corresponding intermediates revealed that the direct upstream intermediates of the strongly regulated enzymes have a lower toxicity (see <xref ref-type="supplementary-material" rid="pcbi.1005371.s004">S2 Fig</xref>). This confirms that intermediates prior to strongly regulated enzymes are used as a buffer for varying demands of product concentrations and therefore have on average lower toxicity.</p>
<fig id="pcbi.1005371.g006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005371.g006</object-id>
<label>Fig 6</label>
<caption>
<title>Comparisons of intermediate toxicity distributions before (left), at (middle) and after strongly regulated enzymes for (A) transcriptional regulation and (B) post-translational regulation.</title>
<p>Yellow color indicates toxicity distributions for strongly regulated enzymes, and white color the corresponding toxicity distributions for direct downstream intermediates of weakly regulated enzymes (lower values indicate higher toxicity).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005371.g006" xlink:type="simple"/>
</fig>
<p>Further, our optimization results are moreover supported by the observation that the downstream intermediates of strongly regulated enzymes are significantly more toxic (Mann–Whitney–Wilcoxon test, <italic>P</italic> = 1.9 ⋅ 10<sup>−12</sup>, see <xref ref-type="fig" rid="pcbi.1005371.g006">Fig 6</xref>). The use of logarithmized IC50 and the subsequent Z-transformation leads to differences of toxicity in the magnitude of 10<sup>−1</sup>. In this case a difference of 10<sup>−1</sup> corresponds to 10% of the variance of the toxicity across the pathway, where IC50 values can easily vary from 10<sup>−4</sup> <italic>g l</italic><sup>−1</sup> for toxic metabolites to 10<sup>2</sup> <italic>g l</italic><sup>−1</sup> for non-toxic metabolites. The positional analysis of intermediate toxicity moreover revealed that highly toxic intermediates are not always directly produced by the strongly regulated enzyme, but can also occur further downstream (see <xref ref-type="supplementary-material" rid="pcbi.1005371.s004">S2 Fig</xref>). As we have seen in our optimization results this can be explained by the influence of enzyme efficiency and the preference of highly efficient enzymes as main regulatory targets.</p>
</sec>
<sec id="sec009">
<title>Efficient enzymes are main targets of transcriptional regulation in <italic>Escherichia coli</italic></title>
<p>In the optimization results, we observed a strong influence of kinetic efficiency of enzymes in combination with intermediate toxicity on the optimal regulatory strategy. Since a large-scale data set for all prokaryotes is not available for kinetic parameters and prediction, we verified our hypotheses in <italic>Escherichia coli</italic>.</p>
<p>We retrieved all experimental determined values of <italic>k</italic><sub><italic>cat</italic></sub> and <italic>K</italic><sub><italic>M</italic></sub> for <italic>Escherichia coli</italic> from the Brenda database [<xref ref-type="bibr" rid="pcbi.1005371.ref025">25</xref>] and obtained 266 enzymes with <italic>k</italic><sub><italic>cat</italic></sub> and <italic>K</italic><sub><italic>M</italic></sub> values as data points. We reduced the number of intervals dividing the pathway positions (first, middle, last) and mapped the properties.</p>
<p>Interestingly, the distribution of <italic>k</italic><sub><italic>eff</italic></sub> shows that the initial enzymes of pathways (11.6 <italic>mM</italic><sup>−1</sup> <italic>s</italic><sup>−1</sup> average efficiency) tend to be much less efficient than the terminal enzymes (94.1 <italic>mM</italic><sup>−1</sup> <italic>s</italic><sup>−1</sup> average efficiency) in a linear pathway (Mann–Whitney–Wilcoxon test, <italic>P</italic> = 5.1 ⋅ 10<sup>−3</sup>, see <xref ref-type="fig" rid="pcbi.1005371.g007">Fig 7A</xref>). This can be explained by the need for a more precise regulation at the terminal step of pathways to fine-tune the synthesis of the product of the pathway according to cellular needs as we reported previously [<xref ref-type="bibr" rid="pcbi.1005371.ref010">10</xref>, <xref ref-type="bibr" rid="pcbi.1005371.ref015">15</xref>]. The distribution of intermediate toxicity is inverse with a lower log IC50 for late intermediates and a higher log IC50 for early intermediates suggesting a relation between intermediate toxicity and kinetic efficiency. This is confirmed by the significant correlation between kinetic efficiency and toxicity (Spearman correlation <italic>r</italic> = −0.14, <italic>P</italic> = 0.022, see <xref ref-type="fig" rid="pcbi.1005371.g007">Fig 7C</xref>) and is linked to the correlation of kinetic efficiency and promoter length (Spearman correlation <italic>r</italic> = −0.16, <italic>P</italic> = 0.009, see <xref ref-type="fig" rid="pcbi.1005371.g007">Fig 7B</xref>). Both relationships between intermediate toxicity, kinetic efficiency and regulation are in line with our optimization results and show that there is a evolutionary selection for efficient enzymes as strongly regulated enzymes optimally controlling toxic intermediate accumulation. Further, the results show a link to the hypothesis of retro-evolution of pathways [<xref ref-type="bibr" rid="pcbi.1005371.ref031">31</xref>], which assumes that pathways are extended by the invention of enzymes which are able to synthesize the product from more distant intermediates and therefore final and evolutionary older enzymes have a higher efficiency. Additionally, the same is true for the toxicity of intermediates, because we see that late intermediates are more toxic than the early intermediates (see <xref ref-type="fig" rid="pcbi.1005371.g005">Fig 5</xref>), which can be seen as evolutionary newer sources for the required product to circumvent toxic intermediates.</p>
<fig id="pcbi.1005371.g007" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005371.g007</object-id>
<label>Fig 7</label>
<caption>
<title/>
<p>Relation of kinetic efficiency and pathway position (A), regulation (B) and product toxicity (C, lower values indicate higher toxicity) in <italic>Escherichia coli</italic>.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005371.g007" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec010">
<title>Using intermediates as endogenous antimicrobials: Acetate as a by-product of lipid <italic>IV</italic><sub><italic>A</italic></sub> biosynthesis in <italic>Escherichia coli</italic></title>
<p>Our results about the interplay of intermediate toxicity, kinetic efficiency and regulation of linear metabolic pathways in prokaryotes have demonstrated the importance of fine tuned regulatory programs for controlling metabolic pathways to avoid the production of toxic intermediates. In the other direction, this suggests that we could use information about strongly regulated enzymes to infer metabolites whose production and consumption is under tight control and hence they might potentially be harmful to the cell. Examples for antimicrobials that follow this principle are antibiotics targeting late steps in the teichoic acid biosynthesis in gram-positive bacteria [<xref ref-type="bibr" rid="pcbi.1005371.ref032">32</xref>]. In this case, late intermediates are accumulated increasing the osmotic stress and enhancing the antimicrobial effect [<xref ref-type="bibr" rid="pcbi.1005371.ref033">33</xref>].</p>
<p>An interesting example is provided by lipid <italic>IV</italic><sub><italic>A</italic></sub> biosynthesis which produces not only lipopolysaccharides precursors as components of the cell wall of <italic>E. coli</italic> but also the toxic byproduct acetate (see <xref ref-type="fig" rid="pcbi.1005371.g008">Fig 8</xref>). Despite the ability of <italic>Escherichia coli</italic> to utilize acetate as a carbon source, higher concentrations of acetate (&gt; 8 <italic>mM</italic>) are reported to inhibit growth by various mechanisms (see green box in <xref ref-type="fig" rid="pcbi.1005371.g008">Fig 8A</xref>) [<xref ref-type="bibr" rid="pcbi.1005371.ref034">34</xref>].</p>
<fig id="pcbi.1005371.g008" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1005371.g008</object-id>
<label>Fig 8</label>
<caption>
<title/>
<p>(A) Excerpt of metabolic context of acetate and lipid <italic>IV</italic><sub><italic>A</italic></sub> biosynthesis. The green box highlights mechanisms of acetate toxicity. (B) lipid <italic>IV</italic><sub><italic>A</italic></sub> biosynthetic pathway including key characteristics (lower log IC50 values indicate higher toxicity).</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005371.g008" xlink:type="simple"/>
</fig>
<p>In agreement with our predictions, the acetate producing enzyme LpxC (UDP-3-O-acyl-N-acetylglucosamine deacetylase) has a very high catalytic efficiency (642.86 <italic>mM</italic><sup>−1</sup> <italic>s</italic><sup>−1</sup>) and the highest promoter length (101 bp) within the pathway (see <xref ref-type="fig" rid="pcbi.1005371.g008">Fig 8B</xref>). This data confirms the description in the literature that this step is the key step of lipid <italic>IV</italic><sub><italic>A</italic></sub> biosynthesis and is tightly controlled by the ATP-dependent metalloprotease FtsH [<xref ref-type="bibr" rid="pcbi.1005371.ref035">35</xref>]. The gene <italic>lpxC</italic> is located in an operon together with several genes controlling cell division. However, <italic>ftsH</italic> is transcribed separately providing a precise regulation and prevents accumulation or depletion of the key enzyme which has been described as lethal in previous studies [<xref ref-type="bibr" rid="pcbi.1005371.ref035">35</xref>, <xref ref-type="bibr" rid="pcbi.1005371.ref036">36</xref>]. However, previous research focused on the discovery of inhibitors to block lipid <italic>IV</italic><sub><italic>A</italic></sub> biosynthesis and subsequently weakening the membrane of prokaryotes. Thus, our results suggest that either inhibiting acetate consuming enzymes or overproducing LpxC represent routes to use acetate as an endogenous antimicrobial. However, overproducing LpxC might have side-effects due to its role in cell wall biosynthesis.</p>
<p>Key mechanisms of acetate toxicity in <italic>E. coli</italic> are summarized in <xref ref-type="fig" rid="pcbi.1005371.g008">Fig 8A</xref>. Acetate is a side-product during mixed acid fermentation where glucose is converted to lactate, acetate, succinate and formate as well as ethanol in anaerobic conditions [<xref ref-type="bibr" rid="pcbi.1005371.ref037">37</xref>]. Moreover, acetate is a major byproduct during growth on excess glucose, referred to as overflow metabolism [<xref ref-type="bibr" rid="pcbi.1005371.ref038">38</xref>], and is produced not only via degradation of acetyl-CoA but also directly by pyruvate oxidation at low growth rates [<xref ref-type="bibr" rid="pcbi.1005371.ref039">39</xref>]. The mechanism behind acetate toxicity is based on several factors. First of all, acetate lowers the pH in the cell [<xref ref-type="bibr" rid="pcbi.1005371.ref034">34</xref>], which impacts many cellular processes like protein folding or ion transport [<xref ref-type="bibr" rid="pcbi.1005371.ref040">40</xref>]. Additionally, acetate inhibits the production of methionine via homocysteine which then accumulates and is also reported as a toxic intermediate [<xref ref-type="bibr" rid="pcbi.1005371.ref034">34</xref>]. To reduce the concentration of acetate the cell can export acetate [<xref ref-type="bibr" rid="pcbi.1005371.ref041">41</xref>], which leads to acetate accumulation in the environment, or convert it to acetyl-CoA, which can be oxidized in the tricarboxylic acid cycle [<xref ref-type="bibr" rid="pcbi.1005371.ref042">42</xref>]. Acetate is converted into acetyl-CoA either via acetate kinase and phosphotransacetylase at high concentrations of acetate, or through the acetyl-CoA synthetase during late exponential phase [<xref ref-type="bibr" rid="pcbi.1005371.ref043">43</xref>]. Therefore both pathways and its enzymes are potential targets for inhibition to induce an accumulation of acetate.</p>
</sec>
</sec>
<sec id="sec011" sec-type="conclusions">
<title>Discussion</title>
<p>In the present study, we used dynamic optimization to elucidate the influence of toxic intermediates on the regulation of linear metabolic pathways. Previous studies showed that toxic intermediates have a high impact on the yield of pathways [<xref ref-type="bibr" rid="pcbi.1005371.ref044">44</xref>] and accumulation is prevented by feedback mechanisms [<xref ref-type="bibr" rid="pcbi.1005371.ref034">34</xref>, <xref ref-type="bibr" rid="pcbi.1005371.ref045">45</xref>] as well as operonic organization [<xref ref-type="bibr" rid="pcbi.1005371.ref046">46</xref>].</p>
<p>Our optimization results disclose that sparsely regulated pathways with strongly regulated enzymes at the first and last position use late intermediates to buffer the varying demand of product concentrations. However, if these intermediates are highly toxic they cannot be used as buffer and regulation needs to target enzymes further upstream. The optimization showed that especially kinetic efficient enzymes are the targets of regulation and hence, the position of the strongly regulated enzyme is strongly influenced by the interplay of intermediate toxicity and kinetic characteristics of a pathway. Together with other factors, like pathway topology or enzyme costs [<xref ref-type="bibr" rid="pcbi.1005371.ref010">10</xref>, <xref ref-type="bibr" rid="pcbi.1005371.ref015">15</xref>], dynamic optimization allowed us to disentangle the influence of many features on pathway control thereby expanding the classical view of pathway regulation like key enzymes and rate limiting steps.</p>
<p>We confirmed the predicted optimality principles by an analysis of pathway regulation on the transcriptional and post-translational level independently across all prokaryotes listed in the BioCyc database by relating enzyme regulation with intermediate toxicity estimations. Further, we showed for <italic>E. coli</italic> that kinetic properties of enzymes correlate with regulatory effort and intermediate toxicity. Our observation have been proven to be robust to changes of our optimization model and validation process by varying pathway characteristics like length, inhibition kinetics and product dilution dynamics.</p>
<p>The findings provide further insight in the complex strategies behind pathway regulation. In recent years, it became more and more apparent that regulation of pathways cannot be described only by metabolic control analysis, feedback mechanisms and other non-dynamical approaches. Our disclosure of toxic intermediates as additional characteristic determining the positions of regulation extends the understanding of pathway regulation and reveals new opportunities for optimizing pathway yield or find targets for antimicrobial interventions.</p>
<p>As shown for the case of lipid <italic>IV</italic><sub><italic>A</italic></sub> of <italic>E. coli</italic>, toxic intermediates and their producing enzymes are targets for antimicrobial interventions. The deliberate deregulation of a pathway can possibly lead to an accumulation of toxic intermediates like acetate, which act as a endogenous antibiotic and kills the cell. Through an analysis of regulatory effort, intermediate toxicity as well as catalytic efficiency, targets can be identified on a large scale supporting the discovery of new antibiotic drugs. This approach could provide more and organism specific targets than the focus of most antibiotics to interfere with the cell wall and its synthesis or the synthesis of DNA and protein [<xref ref-type="bibr" rid="pcbi.1005371.ref047">47</xref>].</p>
<p>Despite the more complex regulation in eukaryotes and different cellular preconditions like the decoupling of transcription and translation, we think that the same optimality principles are valid. This has been shown, for instance, in an metabolic engineering approach in yeast where the avoidance of the accumulation of toxic intermediates allowed for an increased production of a desired product through improved cell viability [<xref ref-type="bibr" rid="pcbi.1005371.ref044">44</xref>].</p>
<p>Especially, our approach and these investigations can be applied to eukaryotic pathogens like the fungal species <italic>Candida albicans</italic> or <italic>Aspergillus fumigatus</italic>. For instance, the ergosterol pathway in fungi is attacked by Amphotericin B, specifically ERG3, synthesized by a gene encoding sterol Delta(5,6)-desaturase, so creating an important intermediate of ergosterol pathway [<xref ref-type="bibr" rid="pcbi.1005371.ref048">48</xref>]. Also azols hit this target leading to the disruption of the pathway and intermediate accumulation, subsequently stopping growth of <italic>Candida albicans</italic> [<xref ref-type="bibr" rid="pcbi.1005371.ref048">48</xref>]. However, the opposite strategy, as explored here, to push ERG3 and other enzyme action such that more toxic intermediates are accumulating has not been investigated for drug development. For instance, ERG11 of <italic>Candida albicans is</italic> a potential target leading to accumulation of intermediates, which was also observed under anaerobic conditions where ERG3 is non-functional [<xref ref-type="bibr" rid="pcbi.1005371.ref048">48</xref>]. As all these enzymes are not present in humans, we consider this as an interesting alternative to explore, not only for <italic>Candida</italic> but also for <italic>Aspergillus fumigatus</italic>. Both fungal pathogens are the main causes of life-threatening invasive mycoses [<xref ref-type="bibr" rid="pcbi.1005371.ref049">49</xref>] and drug development is difficult due to the closer relationship between human and fungi compared to prokaryotes.</p>
</sec>
<sec id="sec012">
<title>Supporting information</title>
<supplementary-material id="pcbi.1005371.s001" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005371.s001" xlink:type="simple">
<label>S1 Text</label>
<caption>
<title>ODE system.</title>
<p>Detailed description and mathematical formulation of ODE system and optimization problem.</p>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1005371.s002" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005371.s002" xlink:type="simple">
<label>S2 Text</label>
<caption>
<title>Robustness of optimality principles.</title>
<p>Analysis of pathway models considering product inhibition, reversible reactions, different pathway lengths and random dilution rates.</p>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1005371.s003" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005371.s003" xlink:type="simple">
<label>S1 Fig</label>
<caption>
<title>Positional relation of regulation, kinetic efficiency and intermediate toxicity from optimization.</title>
<p>Influence of parameters (yellow: toxicity, red: kinetic efficiency) on the regulatory strategy and the position of strongly regulated enzymes (blue) for low enzyme costs (A) and high enzyme costs (B). For each strongly regulated enzyme position (row) arrows indicate the difference of medians of toxicity (<italic>β</italic>) and kinetic efficiency (<italic>k</italic><sub><italic>eff</italic></sub>) between strong and weak regulation at each position. Arrow sizes are scaled to the maximal median difference depicted on the right column.</p>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1005371.s004" mimetype="application/pdf" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005371.s004" xlink:type="simple">
<label>S2 Fig</label>
<caption>
<title>Positional relation of regulation and intermediate toxicity in prokaryotes.</title>
<p>Relation of regulation (A) promoter length and (B) PTM-sites with toxicity of intermediates. Arrows pointing upwards showing higher toxicity thresholds (lower toxicity) and arrows pointing downwards vice versa.</p>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pcbi.1005371.s005" mimetype="application/x-7z-compressed" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1005371.s005" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>Regulation and toxicity of linear pathways across prokaryotic species.</title>
<p>Tables of promoter length and PTM-sites, as well as IC50 of downstream intermediates for each defined reaction of linear metabolic pathway.</p>
<p>(7Z)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>We thank Dr. Pablo Carbonell for providing us with the data of EcoliTox and supporting discussions.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pcbi.1005371.ref001">
<label>1</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Parker</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>Smith</surname> <given-names>JM</given-names></name>, <etal>et al</etal>. <article-title>Optimality theory in evolutionary biology</article-title>. <source>Nature</source>. <year>1990</year>;<volume>348</volume>(<issue>6296</issue>):<fpage>27</fpage>–<lpage>33</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/348027a0" xlink:type="simple">10.1038/348027a0</ext-link></comment></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref002">
<label>2</label>
<mixed-citation publication-type="book" xlink:type="simple">
<name name-style="western"><surname>Heinrich</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Schuster</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Holzhütter</surname> <given-names>HG</given-names></name>. <chapter-title>Mathematical analysis of enzymic reaction systems using optimization principles</chapter-title>. In: <source>EJB Reviews 1991</source>. <publisher-name>Springer</publisher-name>; <year>1992</year>. p. <fpage>167</fpage>–<lpage>187</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1005371.ref003">
<label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Goldsmith</surname> <given-names>TH</given-names></name>. <article-title>Optimization, constraint, and history in the evolution of eyes</article-title>. <source>Quarterly Review of Biology</source>. <year>1990</year>;p. <fpage>281</fpage>–<lpage>322</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/416840" xlink:type="simple">10.1086/416840</ext-link></comment> <object-id pub-id-type="pmid">2146698</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref004">
<label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Alexander</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Optimization and gaits in the locomotion of vertebrates</article-title>. <source>Physiological Reviews</source>. <year>1989</year>;<volume>69</volume>(<issue>4</issue>):<fpage>1199</fpage>–<lpage>1227</lpage>. <object-id pub-id-type="pmid">2678167</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref005">
<label>5</label>
<mixed-citation publication-type="book" xlink:type="simple">
<name name-style="western"><surname>Lenhart</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Workman</surname> <given-names>JT</given-names></name>. <source>Optimal control applied to biological models</source>. <publisher-name>CRC Press</publisher-name>; <year>2007</year>.</mixed-citation>
</ref>
<ref id="pcbi.1005371.ref006">
<label>6</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Orth</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Thiele</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Palsson</surname> <given-names>BØ</given-names></name>. <article-title>What is flux balance analysis?</article-title> <source>Nature Biotechnology</source>. <year>2010</year>;<volume>28</volume>(<issue>3</issue>):<fpage>245</fpage>–<lpage>248</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nbt.1614" xlink:type="simple">10.1038/nbt.1614</ext-link></comment> <object-id pub-id-type="pmid">20212490</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref007">
<label>7</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Adiwijaya</surname> <given-names>BS</given-names></name>, <name name-style="western"><surname>Barton</surname> <given-names>PI</given-names></name>, <name name-style="western"><surname>Tidor</surname> <given-names>B</given-names></name>. <article-title>Biological network design strategies: discovery through dynamic optimization</article-title>. <source>Molecular BioSystems</source>. <year>2006</year>;<volume>2</volume>(<issue>12</issue>):<fpage>650</fpage>–<lpage>659</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1039/b610090b" xlink:type="simple">10.1039/b610090b</ext-link></comment> <object-id pub-id-type="pmid">17216046</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref008">
<label>8</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Zaslaver</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Mayo</surname> <given-names>AE</given-names></name>, <name name-style="western"><surname>Rosenberg</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Bashkin</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Sberro</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Tsalyuk</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Just-in-time transcription program in metabolic pathways</article-title>. <source>Nature Genetics</source>. <year>2004</year>;<volume>36</volume>(<issue>5</issue>):<fpage>486</fpage>–<lpage>491</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng1348" xlink:type="simple">10.1038/ng1348</ext-link></comment> <object-id pub-id-type="pmid">15107854</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref009">
<label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Banga</surname> <given-names>JR</given-names></name>. <article-title>Optimization in computational systems biology</article-title>. <source>BMC Systems Biology</source>. <year>2008</year>;<volume>2</volume>(<issue>1</issue>):<fpage>47</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1752-0509-2-47" xlink:type="simple">10.1186/1752-0509-2-47</ext-link></comment> <object-id pub-id-type="pmid">18507829</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref010">
<label>10</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Wessely</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Bartl</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Guthke</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Schuster</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kaleta</surname> <given-names>C</given-names></name>. <article-title>Optimal regulatory strategies for metabolic pathways in <italic>Escherichia coli</italic> depending on protein costs</article-title>. <source>Molecular Systems Biology</source>. <year>2011</year>;<volume>7</volume>(<issue>1</issue>):<fpage>515</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/msb.2011.46" xlink:type="simple">10.1038/msb.2011.46</ext-link></comment> <object-id pub-id-type="pmid">21772263</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref011">
<label>11</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Fischer</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Sauer</surname> <given-names>U</given-names></name>. <article-title>Large-scale in vivo flux analysis shows rigidity and suboptimal performance of <italic>Bacillus subtilis</italic> metabolism</article-title>. <source>Nature Genetics</source>. <year>2005</year>;<volume>37</volume>(<issue>6</issue>):<fpage>636</fpage>–<lpage>640</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng1555" xlink:type="simple">10.1038/ng1555</ext-link></comment> <object-id pub-id-type="pmid">15880104</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref012">
<label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Schuetz</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Zamboni</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Zampieri</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Heinemann</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Sauer</surname> <given-names>U</given-names></name>. <article-title>Multidimensional optimality of microbial metabolism</article-title>. <source>Science</source>. <year>2012</year>;<volume>336</volume>(<issue>6081</issue>):<fpage>601</fpage>–<lpage>604</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/science.1216882" xlink:type="simple">10.1126/science.1216882</ext-link></comment> <object-id pub-id-type="pmid">22556256</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref013">
<label>13</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Geisel</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Vilar</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Rubi</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Thattai</surname> <given-names>M</given-names></name>. <article-title>Optimal resting-growth strategies of microbial populations in fluctuating environments</article-title>. <source>PLOS ONE</source>. <year>2011</year>;<volume>6</volume>(<issue>4</issue>):<fpage>e18622</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0018622" xlink:type="simple">10.1371/journal.pone.0018622</ext-link></comment> <object-id pub-id-type="pmid">21525975</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref014">
<label>14</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Bartl</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kötzing</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Schuster</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Kaleta</surname> <given-names>C</given-names></name>. <article-title>Dynamic optimization identifies optimal programmes for pathway regulation in prokaryotes</article-title>. <source>Nature Communications</source>. <year>2013</year>;<volume>4</volume>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ncomms3243" xlink:type="simple">10.1038/ncomms3243</ext-link></comment> <object-id pub-id-type="pmid">23979724</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref015">
<label>15</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>de Hijas-Liste</surname> <given-names>GM</given-names></name>, <name name-style="western"><surname>Balsa-Canto</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Ewald</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Bartl</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Banga</surname> <given-names>JR</given-names></name>, <etal>et al</etal>. <article-title>Optimal programs of pathway control: dissecting the influence of pathway topology and feedback inhibition on pathway regulation</article-title>. <source>BMC Bioinformatics</source>. <year>2015</year>;<volume>16</volume>(<issue>1</issue>):<fpage>163</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s12859-015-0587-z" xlink:type="simple">10.1186/s12859-015-0587-z</ext-link></comment> <object-id pub-id-type="pmid">25982966</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref016">
<label>16</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Ewald</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kötzing</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Bartl</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kaleta</surname> <given-names>C</given-names></name>. <article-title>Footprints of Optimal Protein Assembly Strategies in the Operonic Structure of Prokaryotes</article-title>. <source>Metabolites</source>. <year>2015</year>;<volume>5</volume>(<issue>2</issue>):<fpage>252</fpage>–<lpage>269</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3390/metabo5020252" xlink:type="simple">10.3390/metabo5020252</ext-link></comment> <object-id pub-id-type="pmid">25927816</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref017">
<label>17</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Loret</surname> <given-names>MO</given-names></name>, <name name-style="western"><surname>Pedersen</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>François</surname> <given-names>J</given-names></name>. <article-title>Revised procedures for yeast metabolites extraction: application to a glucose pulse to carbon-limited yeast cultures, which reveals a transient activation of the purine salvage pathway</article-title>. <source>Yeast</source>. <year>2007</year>;<volume>24</volume>(<issue>1</issue>):<fpage>47</fpage>–<lpage>60</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/yea.1435" xlink:type="simple">10.1002/yea.1435</ext-link></comment> <object-id pub-id-type="pmid">17192850</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref018">
<label>18</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Arévalo-Rodríguez</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Pan</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Boeke</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Heitman</surname> <given-names>J</given-names></name>. <article-title>FKBP12 controls aspartate pathway flux in <italic>Saccharomyces cerevisiae</italic> to prevent toxic intermediate accumulation</article-title>. <source>Eukaryotic Cell</source>. <year>2004</year>;<volume>3</volume>(<issue>5</issue>):<fpage>1287</fpage>–<lpage>1296</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/EC.3.5.1287-1296.2004" xlink:type="simple">10.1128/EC.3.5.1287-1296.2004</ext-link></comment> <object-id pub-id-type="pmid">15470257</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref019">
<label>19</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Kingsbury</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>McCusker</surname> <given-names>JH</given-names></name>. <article-title>Homoserine toxicity in <italic>Saccharomyces cerevisiae</italic> and <italic>Candida albicans</italic> homoserine kinase (thr1Δ) mutants</article-title>. <source>Eukaryotic Cell</source>. <year>2010</year>;<volume>9</volume>(<issue>5</issue>):<fpage>717</fpage>–<lpage>728</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/EC.00044-10" xlink:type="simple">10.1128/EC.00044-10</ext-link></comment> <object-id pub-id-type="pmid">20305002</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref020">
<label>20</label>
<mixed-citation publication-type="book" xlink:type="simple">
<name name-style="western"><surname>Berg</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Held</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Stryer</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Lange</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Mahlke</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Maxam</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <source>Stryer Biochemie</source>. <publisher-name>Springer</publisher-name> <publisher-loc>Berlin Heidelberg</publisher-loc>; <year>2015</year>.</mixed-citation>
</ref>
<ref id="pcbi.1005371.ref021">
<label>21</label>
<mixed-citation publication-type="book" xlink:type="simple">
<name name-style="western"><surname>Heinrich</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Schuster</surname> <given-names>S</given-names></name>. <source>The regulation of cellular systems</source>. <publisher-name>Springer Science &amp; Business Media</publisher-name>; <year>2012</year>.</mixed-citation>
</ref>
<ref id="pcbi.1005371.ref022">
<label>22</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Bartl</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Biegler</surname> <given-names>LT</given-names></name>. <article-title>Improvement of state profile accuracy in nonlinear dynamic optimization with the quasi-sequential approach</article-title>. <source>AIChE Journal</source>. <year>2011</year>;<volume>57</volume>(<issue>8</issue>):<fpage>2185</fpage>–<lpage>2197</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/aic.12437" xlink:type="simple">10.1002/aic.12437</ext-link></comment></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref023">
<label>23</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Bratley</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Fox</surname> <given-names>BL</given-names></name>. <article-title>Algorithm 659: Implementing Sobol’s quasirandom sequence generator</article-title>. <source>ACM Transactions on Mathematical Software (TOMS)</source>. <year>1988</year>;<volume>14</volume>(<issue>1</issue>):<fpage>88</fpage>–<lpage>100</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1145/42288.214372" xlink:type="simple">10.1145/42288.214372</ext-link></comment></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref024">
<label>24</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Caspi</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Altman</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Billington</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Dreher</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Foerster</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Fulcher</surname> <given-names>CA</given-names></name>, <etal>et al</etal>. <article-title>The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of Pathway/Genome Databases</article-title>. <source>Nucleic Acids Research</source>. <year>2014</year>;<volume>42</volume>(<issue>D1</issue>):<fpage>D459</fpage>–<lpage>D471</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/nar/gkt1103" xlink:type="simple">10.1093/nar/gkt1103</ext-link></comment> <object-id pub-id-type="pmid">24225315</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref025">
<label>25</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Chang</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Schomburg</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Placzek</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Jeske</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Ulbrich</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Xiao</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>BRENDA in 2015: exciting developments in its 25th year of existence</article-title>. <source>Nucleic Acids Research</source>. <year>2014</year>;p. <fpage>gku1068</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1005371.ref026">
<label>26</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Lu</surname> <given-names>CT</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>KY</given-names></name>, <name name-style="western"><surname>Su</surname> <given-names>MG</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>TY</given-names></name>, <name name-style="western"><surname>Bretaña</surname> <given-names>NA</given-names></name>, <name name-style="western"><surname>Chang</surname> <given-names>WC</given-names></name>, <etal>et al</etal>. <article-title>DbPTM 3.0: an informative resource for investigating substrate site specificity and functional association of protein post-translational modifications</article-title>. <source>Nucleic Acids Research</source>. <year>2012</year>;p. <fpage>gks1229</fpage>.</mixed-citation>
</ref>
<ref id="pcbi.1005371.ref027">
<label>27</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Sharp</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>WH</given-names></name> <article-title>The codon adaptation index-a measure of directional synonymous codon usage bias, and its potential applications</article-title> <source>Nucleic acids research</source>. <year>1987</year>;<volume>15</volume>(<issue>3</issue>):<fpage>1281</fpage>–<lpage>1295</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/nar/15.3.1281" xlink:type="simple">10.1093/nar/15.3.1281</ext-link></comment> <object-id pub-id-type="pmid">3547335</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref028">
<label>28</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Planson</surname> <given-names>AG</given-names></name>, <name name-style="western"><surname>Carbonell</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Paillard</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Pollet</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Faulon</surname> <given-names>JL</given-names></name>. <article-title>Compound toxicity screening and structure–activity relationship modeling in <italic>Escherichia coli</italic></article-title>. <source>Biotechnology and Bioengineering</source>. <year>2012</year>;<volume>109</volume>(<issue>3</issue>):<fpage>846</fpage>–<lpage>850</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/bit.24356" xlink:type="simple">10.1002/bit.24356</ext-link></comment> <object-id pub-id-type="pmid">22038678</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref029">
<label>29</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Atkinson</surname> <given-names>DE</given-names></name>. <article-title>Limitation of Metabolite Concentrations and the Conservation of Solvent Capacity in the Living Cell</article-title>. <source>Current Topics in Cellular Regulation</source>. <year>1969</year>;<volume>1</volume>:<fpage>29</fpage>–<lpage>43</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/B978-0-12-152801-0.50007-9" xlink:type="simple">10.1016/B978-0-12-152801-0.50007-9</ext-link></comment></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref030">
<label>30</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Schuster</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Heinrich</surname> <given-names>R</given-names></name>. <article-title>Minimization of intermediate concentrations as a suggested optimality principle for biochemical networks</article-title>. <source>Journal of Mathematical Biology</source>. <year>1991</year>;<volume>29</volume>(<issue>5</issue>):<fpage>425</fpage>–<lpage>442</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/BF00160471" xlink:type="simple">10.1007/BF00160471</ext-link></comment></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref031">
<label>31</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Schmidt</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sunyaev</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Bork</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Dandekar</surname> <given-names>T</given-names></name>. <article-title>Metabolites: a helping hand for pathway evolution?</article-title> <source>Trends in biochemical sciences</source>. <year>2003</year>;<volume>28</volume>(<issue>6</issue>):<fpage>336</fpage>–<lpage>341</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0968-0004(03)00114-2" xlink:type="simple">10.1016/S0968-0004(03)00114-2</ext-link></comment> <object-id pub-id-type="pmid">12826406</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref032">
<label>32</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>D’Elia</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Pereira</surname> <given-names>MP</given-names></name>, <name name-style="western"><surname>Chung</surname> <given-names>YS</given-names></name>, <name name-style="western"><surname>Zhao</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Chau</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kenney</surname> <given-names>TJ</given-names></name>, <etal>et al</etal>. <article-title>Lesions in teichoic acid biosynthesis in <italic>Staphylococcus aureus</italic> lead to a lethal gain of function in the otherwise dispensable pathway</article-title>. <source>Journal of Bacteriology</source>. <year>2006</year>;<volume>188</volume>(<issue>12</issue>):<fpage>4183</fpage>–<lpage>4189</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JB.00197-06" xlink:type="simple">10.1128/JB.00197-06</ext-link></comment> <object-id pub-id-type="pmid">16740924</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref033">
<label>33</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Sewell</surname> <given-names>EW</given-names></name>, <name name-style="western"><surname>Brown</surname> <given-names>ED</given-names></name>. <article-title>Taking aim at wall teichoic acid synthesis: new biology and new leads for antibiotics</article-title>. <source>The Journal of Antibiotics</source>. <year>2014</year>;<volume>67</volume>(<issue>1</issue>):<fpage>43</fpage>–<lpage>51</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ja.2013.100" xlink:type="simple">10.1038/ja.2013.100</ext-link></comment> <object-id pub-id-type="pmid">24169797</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref034">
<label>34</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Roe</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>O’Byrne</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>McLaggan</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Booth</surname> <given-names>IR</given-names></name>. <article-title>Inhibition of <italic>Escherichia coli</italic> growth by acetic acid: a problem with methionine biosynthesis and homocysteine toxicity</article-title>. <source>Microbiology</source>. <year>2002</year>;<volume>148</volume>(<issue>7</issue>):<fpage>2215</fpage>–<lpage>2222</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1099/00221287-148-7-2215" xlink:type="simple">10.1099/00221287-148-7-2215</ext-link></comment> <object-id pub-id-type="pmid">12101308</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref035">
<label>35</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Führer</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Langklotz</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Narberhaus</surname> <given-names>F</given-names></name>. <article-title>The C-terminal end of LpxC is required for degradation by the FtsH protease</article-title>. <source>Molecular Microbiology</source>. <year>2006</year>;<volume>59</volume>(<issue>3</issue>):<fpage>1025</fpage>–<lpage>1036</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1365-2958.2005.04994.x" xlink:type="simple">10.1111/j.1365-2958.2005.04994.x</ext-link></comment> <object-id pub-id-type="pmid">16420369</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref036">
<label>36</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Clements</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Coignard</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Johnson</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Chandler</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Palan</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Waller</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Antibacterial activities and characterization of novel inhibitors of LpxC</article-title>. <source>Antimicrobial Agents and Chemotherapy</source>. <year>2002</year>;<volume>46</volume>(<issue>6</issue>):<fpage>1793</fpage>–<lpage>1799</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.46.6.1793-1799.2002" xlink:type="simple">10.1128/AAC.46.6.1793-1799.2002</ext-link></comment> <object-id pub-id-type="pmid">12019092</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref037">
<label>37</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Xu</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Jahic</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Blomsten</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Enfors</surname> <given-names>SO</given-names></name>. <article-title>Glucose overflow metabolism and mixed-acid fermentation in aerobic large-scale fed-batch processes with <italic>Escherichia coli</italic></article-title>. <source>Applied Microbiology and Biotechnology</source>. <year>1999</year>;<volume>51</volume>(<issue>5</issue>):<fpage>564</fpage>–<lpage>571</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s002530051433" xlink:type="simple">10.1007/s002530051433</ext-link></comment> <object-id pub-id-type="pmid">10390814</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref038">
<label>38</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Meyer</surname> <given-names>HP</given-names></name>, <name name-style="western"><surname>Leist</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Fiechter</surname> <given-names>A</given-names></name>. <article-title>Acetate formation in continuous culture of Escherichia coli K12 D1 on defined and complex media</article-title>. <source>Journal of Biotechnology</source>. <year>1984</year>;<volume>1</volume>(<issue>5</issue>):<fpage>355</fpage>–<lpage>358</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/0168-1656(84)90027-0" xlink:type="simple">10.1016/0168-1656(84)90027-0</ext-link></comment></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref039">
<label>39</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Abdel-Hamid</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Attwood</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Guest</surname> <given-names>JR</given-names></name>. <article-title>Pyruvate oxidase contributes to the aerobic growth efficiency of <italic>Escherichia coli</italic></article-title>. <source>Microbiology</source>. <year>2001</year>;<volume>147</volume>(<issue>6</issue>):<fpage>1483</fpage>–<lpage>1498</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1099/00221287-147-6-1483" xlink:type="simple">10.1099/00221287-147-6-1483</ext-link></comment> <object-id pub-id-type="pmid">11390679</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref040">
<label>40</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Booth</surname> <given-names>IR</given-names></name>. <article-title>Regulation of cytoplasmic pH in bacteria</article-title>. <source>Microbiological Reviews</source>. <year>1985</year>;<volume>49</volume>(<issue>4</issue>):<fpage>359</fpage>. <object-id pub-id-type="pmid">3912654</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref041">
<label>41</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Joana</surname> <given-names>SP</given-names></name>, <name name-style="western"><surname>Sandra</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>David</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Ines</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Sandra</surname> <given-names>CV</given-names></name>, <name name-style="western"><surname>Cecilia</surname> <given-names>MA</given-names></name>, <etal>et al</etal>. <article-title>SATP (YaaH), a succinate-acetate transporter protein in <italic>Escherichia coli</italic></article-title>. <source>Biochemical Journal</source>. <year>2013</year>;<volume>454</volume>(<issue>3</issue>):<fpage>585</fpage>–<lpage>595</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1042/BJ20130412" xlink:type="simple">10.1042/BJ20130412</ext-link></comment></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref042">
<label>42</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Brown</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Jones-Mortimer</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kornberg</surname> <given-names>H</given-names></name>. <article-title>The enzymic interconversion of acetate and acetyl-coenzyme A in <italic>Escherichia coli</italic></article-title>. <source>Journal of General Microbiology</source>. <year>1977</year>;<volume>102</volume>(<issue>2</issue>):<fpage>327</fpage>–<lpage>336</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1099/00221287-102-2-327" xlink:type="simple">10.1099/00221287-102-2-327</ext-link></comment> <object-id pub-id-type="pmid">21941</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref043">
<label>43</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Kumari</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Beatty</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Browning</surname> <given-names>DF</given-names></name>, <name name-style="western"><surname>Busby</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Simel</surname> <given-names>EJ</given-names></name>, <name name-style="western"><surname>Hovel-Miner</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Regulation of acetyl coenzyme A synthetase in <italic>Escherichia coli</italic></article-title>. <source>Journal of Bacteriology</source>. <year>2000</year>;<volume>182</volume>(<issue>15</issue>):<fpage>4173</fpage>–<lpage>4179</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JB.182.15.4173-4179.2000" xlink:type="simple">10.1128/JB.182.15.4173-4179.2000</ext-link></comment> <object-id pub-id-type="pmid">10894724</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref044">
<label>44</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Keasling</surname> <given-names>JD</given-names></name>. <article-title>Manufacturing molecules through metabolic engineering</article-title>. <source>Science</source>. <year>2010</year>;<volume>330</volume>(<issue>6009</issue>):<fpage>1355</fpage>–<lpage>1358</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/science.1193990" xlink:type="simple">10.1126/science.1193990</ext-link></comment> <object-id pub-id-type="pmid">21127247</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref045">
<label>45</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Dahl</surname> <given-names>RH</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Alonso-Gutierrez</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Baidoo</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Batth</surname> <given-names>TS</given-names></name>, <name name-style="western"><surname>Redding-Johanson</surname> <given-names>AM</given-names></name>, <etal>et al</etal>. <article-title>Engineering dynamic pathway regulation using stress-response promoters</article-title>. <source>Nature Biotechnology</source>. <year>2013</year>;<volume>31</volume>(<issue>11</issue>):<fpage>1039</fpage>–<lpage>1046</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nbt.2689" xlink:type="simple">10.1038/nbt.2689</ext-link></comment> <object-id pub-id-type="pmid">24142050</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref046">
<label>46</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Pfleger</surname> <given-names>BF</given-names></name>, <name name-style="western"><surname>Pitera</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>Smolke</surname> <given-names>CD</given-names></name>, <name name-style="western"><surname>Keasling</surname> <given-names>JD</given-names></name>. <article-title>Combinatorial engineering of intergenic regions in operons tunes expression of multiple genes</article-title>. <source>Nature Biotechnology</source>. <year>2006</year>;<volume>24</volume>(<issue>8</issue>):<fpage>1027</fpage>–<lpage>1032</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nbt1226" xlink:type="simple">10.1038/nbt1226</ext-link></comment> <object-id pub-id-type="pmid">16845378</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref047">
<label>47</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Cloutier</surname> <given-names>MJ</given-names></name>. <article-title>Antibiotics: Mechanisms of Action and Acquisition of Resistance–When Magic Bullets Lose Their Magic</article-title>. <source>American Journal of Pharmaceutical Education</source>. <year>1995</year>;<volume>59</volume>(<issue>2</issue>):<fpage>167</fpage>–<lpage>172</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1005371.ref048">
<label>48</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Sanglard</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Ischer</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Parkinson</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Falconer</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Bille</surname> <given-names>J</given-names></name>. <article-title>Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents</article-title>. <source>Antimicrobial Agents and Chemotherapy</source>. <year>2003</year>;<volume>47</volume>(<issue>8</issue>):<fpage>2404</fpage>–<lpage>2412</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.47.8.2404-2412.2003" xlink:type="simple">10.1128/AAC.47.8.2404-2412.2003</ext-link></comment> <object-id pub-id-type="pmid">12878497</object-id></mixed-citation>
</ref>
<ref id="pcbi.1005371.ref049">
<label>49</label>
<mixed-citation publication-type="journal" xlink:type="simple">
<name name-style="western"><surname>Kullberg</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Oude</surname> <given-names>LA</given-names></name>. <article-title>Epidemiology of opportunistic invasive mycoses</article-title>. <source>European journal of medical research</source>. <year>2002</year>;<volume>7</volume>(<issue>5</issue>):<fpage>183</fpage>–<lpage>191</lpage>. <object-id pub-id-type="pmid">12069910</object-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>